Clinical trials: Cutaneous Melanoma, Stage II
Melanoma (Skin)
Vaccine Therapy and Interleukin-12 in Treating Patients With Metastatic Melanoma
RATIONALE: Vaccines made from a tumor antigen gene may make the body build an immune response to kill tumor cells. Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood…
- Trial name
- NCT00002952
- Testing
- MART-1 antigen, recombinant MAGE-3.1 antigen, recombinant interleukin-12
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Chicago